title: [Predictive factors of response to anthracyclines neoadjuvant chemotherapy in breast cancer].
abstract: OBJECTIVE
  Anthracyclines chemotherapy remains primordial and impossible to circumvent in the treatment of breast cancer, in the adjuvant, metastatic and neoadjuvant setting. But some breast invasive tumors are resistant to anthracyclines. The neoadjuvant model is ideal to test the chemosensibility by selecting the well-responder patients and identifying the predictive factors of this response.
  
  
  METHODS
  We report a retrospective study of 126 patients treated at our institute during 2 years (January 2003-December 2004) for a breast cancer with primary chemotherapy. All the patients received anthracyclines according to protocol AC60 (doxorubicine plus cyclophosphamide).
  
  
  RESULTS
  The clinical objective response rate (RO) was 67 % with a complete clinical response (RC) of 11 %. We found a pathological complete response (pCR) in seven patients (5,6 %) of the 126 cases. The statistical study identifies only two clinical factors as predictive of RC and pCR: tumoral size T2-T3 and clinical nodal status N0-N1, while the SBR grading and the hormonal receptors were not correlated.
  
  
  CONCLUSIONS
  Some clinical and histological factors are recognized as predictive for the benefit of anthracyclines neoadjuvant chemotherapy, and correlated to the pCR; we discuss our results through those of the literature, by exposing the current data.
authors.affiliation: Service d'oncologie médicale, Institut national d'oncologie, BP 6213, avenue Allal-El-Fassi, Rabat, Maroc. yoss.onco@hotmail.com
authors.forename: Y
authors.initials: Y
authors.lastname: Bensouda
authors.forename: N
authors.initials: N
authors.lastname: Ismaili
authors.forename: N
authors.initials: N
authors.lastname: Ahbeddou
authors.forename: K
authors.initials: K
authors.lastname: El Hassani
authors.forename: M
authors.initials: M
authors.lastname: Chenna
authors.forename: Y
authors.initials: Y
authors.lastname: Sbitti
authors.forename: S
authors.initials: S
authors.lastname: Boutayeb
authors.forename: H
authors.initials: H
authors.lastname: Errihani
mesh_terms: D000328:Adult; D000368:Aged; D018943:Anthracyclines / Q000008:administration & dosage / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000473:pathology; D003520:Cyclophosphamide / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D019008:Drug Resistance, Neoplasm; D005260:Female; D006801:Humans; D008198:Lymph Nodes / Q000473:pathology; D008875:Middle Aged; D020360:Neoadjuvant Therapy; D009361:Neoplasm Invasiveness; D012189:Retrospective Studies; D016896:Treatment Outcome
chemical_list: D018943:Anthracyclines; D004317:Doxorubicin; D003520:Cyclophosphamide